• Portrait of Jody Haigh
  • Professor

    Max Rady College of Medicine
    Pharmacology and Therapeutics
    Research Institute in Oncology and Hematology (RIOH)
    Room ON5029, 675 McDermot Avenue
    University of Manitoba
    Winnipeg, Manitoba R3E 0V9

    Phone: 204-787-2134


Senior Scientist, Research Institute in Oncology and Hematology (RIOH), CancerCare Manitoba

Accepting graduate students

Research themes

Research interests


Research affiliations

Research groups

Research summary

Dr. Jody Haigh’s research group is interested in the role that misexpression of ZEB and SNAI families of transcription factors has on blood cell development and function that ultimately drives leukemic transformation.

They use both conditional Cre/loxP dependent gain and loss of function mouse models, leukemic cell lines and primary patient leukemic cells to identify novel druggable targets and combination therapies that can be used to fight aggressive forms of blood cancers.

Dr. Haigh has a long-standing interest in cell plasticity, and it pertains to differentiation-based therapies in cancers and in regeneration-based approaches within the blood system and beyond.


Dr. Jody Haigh is an associate professor in pharmacology and therapeutics at the University of Manitoba.

He completed his undergraduate degree in life sciences and master of science degree in biochemistry at Queen’s University. This was followed by a PhD in biochemistry at the IMP/University of Vienna, Austria.

He spent four years as a postdoctoral fellow in the lab of Dr. Andras Nagy at the Samuel Lunenfeld Research Institute at Mount Sinai hospital in Toronto.

From 2004-2013 he was an assistant professor at Ghent University in Belgium and ran his own research group at the VIB.

Dr. Haigh was then recruited to the Australian Centre for Blood Diseases (ACBD) at Monash University in Melbourne, Australia on a Larkin’s Fellowship as an associate professor.

In July 2018, he returned home to Canada as an associate professor of pharmacology and therapeutics and has re-established his research group at the Research Institute in Oncology and Hematology at CancerCare Manitoba/UM Bannatyne campus.

Throughout his career, he has developed and used novel mouse embryonic stem (ES) cell-based transgenic technologies to study genes involved in cardiovascular and hematopoietic development and disease related processes.

He has co-authored numerous publications on the role of vascular endothelial growth factor signaling in organogenesis and disease processes including cancer.

Over the last several years his group has started to work on understanding the role that the epithelial to mesenchymal transition (EMT) transcriptional modulators of the ZEB and SNAI family play in blood development and leukemia and leukemic stem cells.

He has had a long-standing interest in the molecular basis of cellular (de) differentiation, cellular reprogramming and cellular memory.

He has co-authored 90 research articles in journals such as Blood, Cell Reports, Nature, Nature Medicine, Nature Cell Biology, and Nature Communications.

His publications have been cited more than 7,000 times.



Google Scholar profile

Visit Jody Haigh's Google Scholar profile for a complete listing.

Jody Haigh's profile

Contact us

Pharmacology and Therapeutics
Max Rady College of Medicine
A205 Chown Bldg., 753 McDermot Avenue
University of Manitoba (Bannatyne campus)
Winnipeg, MB R3E 0T6 Canada